Download full-text PDF |
Source |
---|
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.
View Article and Find Full Text PDFThe pharmaceutical industry is currently faced with increasing pressure due to patent expirations for block busters, healthcare reforms with strained budgets and growing demands for approval by administrative organizations like the FDA and the EMA. High attrition rates especially in the later expensive stages of the drug development process ask for thoroughly validated drug targets at the beginning of such projects. The great potential of RNA interference strategies toward reaching this goal is outlined in this article.
View Article and Find Full Text PDFMod Healthc
February 2011
Center for American Progress, Washington, USA.
Ann Pharmacother
May 2009
Tardive Dyskinesia Assessment Clinic, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417, USA.
While the development of personalized or molecular medicine is a laudable goal, there remain multiple barriers to its implementation. For example, little is known about the functions of noncoding regions of DNA, as well as the interplay of drug response, environmental factors, and the patient's genetic profile. In addition, there is a constant influx of new information on genetic factors such as epigenetic variation that could further complicate the development of medications based on the genetic profile, as well as the cost of profiling.
View Article and Find Full Text PDFHosp Mater Manage
November 2007
Strategic Initiatives In Healthcare, LLC, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!